Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
24.76
-0.55 (-2.17%)
At close: Nov 3, 2025, 4:00 PM EST
25.24
+0.48 (1.94%)
After-hours: Nov 3, 2025, 5:18 PM EST
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 342 employees as of December 31, 2024. The number of employees increased by 46 or 15.54% compared to the previous year.
Employees
342
Change (1Y)
46
Growth (1Y)
15.54%
Revenue / Employee
$929,617
Profits / Employee
-$129,602
Market Cap
3.03B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 342 | 46 | 15.54% |
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Dec 31, 2020 | 54 | 25 | 86.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARQT News
- 4 days ago - Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments - GlobeNewsWire
- 4 days ago - Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 - GlobeNewsWire
- 5 days ago - Arcutis' Q3 Earnings: Increased Foam Share, Better GTN, And Clear 2026 Guide Made Share Rally - Seeking Alpha
- 6 days ago - Arcutis Biotherapeutics, Inc. (ARQT) Analyst/Investor Day Transcript - Seeking Alpha
- 6 days ago - Arcutis Biotherapeutics: Soaring On Q3 Earnings - Further Upside Likely (Upgrade) - Seeking Alpha
- 6 days ago - Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results - GlobeNewsWire
- 7 days ago - Arcutis to Present at Upcoming Investor Conferences - GlobeNewsWire
- 10 days ago - Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference - GlobeNewsWire